Tirzepatide (40 mg Monthly Dose)

Description

Tirzepatide (40 mg Monthly Dose)

Effects

Promotes significant weight loss (up to 20-25% in studies), suppresses appetite, enhances satiety, improves insulin sensitivity, lowers HbA1c, reduces visceral fat, and improves cardiovascular/lipid profiles.

Applications

Research on obesity, type 2 diabetes, metabolic syndrome.

Side effects

Gastrointestinal (nausea, vomiting, diarrhea, constipation—dose-dependent); rare pancreatitis, gallbladder issues, thyroid concerns.

Notes

40 mg monthly aligns with higher research protocols (~10 mg/week equivalent). FDA-approved versions (Mounjaro/Zepbound) for diabetes/weight loss.